Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

141 questions · 144 findings · 8 reviews

No studies found 34 · 23.6%GRADE not reported 1 · 0.7%Very low 26 · 18.1%Low 55 · 38.2%Moderate 28 · 19.4%High 0 · 0%

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors showed no clear difference in fatal or nonfatal myocardial infarction Median compared with placebo or no treatment (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to macroalbuminuria Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs placebo or no treatment

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors changes micro‐ to normoalbuminuria Median compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Death (all causes) · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in all‐cause death Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Cardiovascular mortality · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in cardiovascular death Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Doubling of SCr Median · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in doubling of SCr Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Fatal or nonfatal stroke · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal stroke Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Fatal or nonfatal myocardial infarction · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in fatal or nonfatal myocardial infarction Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Micro‐ to macroalbuminuria Median · people with diabetes and kidney disease

It is very uncertain whether angiotensin‐converting‐enzyme inhibitors (ACEi) alone changes micro‐ to macroalbuminuria Median compared with ACEi plus angiotensin receptor blockers (very low certainty).

1 finding from 1 review

Angiotensin‐converting enzyme inhibitors vs ACEi plus angiotensin receptor blockers

Micro‐ to normoalbuminuria Median · people with diabetes and kidney disease

Angiotensin‐converting‐enzyme inhibitors (ACEi) alone showed no clear difference in micro‐ to normoalbuminuria Median compared with ACEi plus angiotensin receptor blockers (low certainty).

1 finding from 1 review